Koraishy Research


“Investigating the association of posttraumatic stress disorder (PTSD) with chronic kidney disease (CKD) in World Trade Center (WTC) responders
Extramural- R21 grant (Dept. of Health and Human Services and Centers for Disease Control and Prevention)
PI: Dr. Farrukh M. Koraishy”


Dr. Farrukh Koraishy received a $30,000 SUNY multidisciplinary small team grant for his proposal: “Using Machine Learning to develop CKD risk prediction models in patients with PTSD."

Dr. Farrukh Koraishy received the SUNY seed grant in April 2020 for his study, "Characterization of AKI and testing the use of Losartan in hospitalized patients with COVID-19".



1.       Chaudhri I, Koraishy FM (co-first author), Bolotova O, Yoo J, Marcos LA, Taub T, Sahib H, Bloom M, Ahmad S, Skopicki H and Mallipattu SK. Outcomes associated with the use of RAAS Blockade in hospitalized patients with SARS-CoV-2 infection. Kidney360 June 2020, 10.34067/KID.0003792020.
2.       Vest LS, Sarabu N, Koraishy FM, Nguyen MT, Park M, Lam NN, Schnitzler MA, Axelrod D, Hsu CY, Garg AX, Segev DL, Massie AB, Hess GP, Kasiske BL, Lentine KL. Prescription patterns of opioids and non-steroidal anti-inflammatory drugs in the first year after living kidney donation: An analysis of U.S. Registry and Pharmacy fill records. Clin Transplant. 2020 Jun 5:e14000.
3.       Koraishy FM, Rohatgi R. Telenephrology: An Emerging Platform for Delivering Renal Health Care. Am J Kidney Dis. 2020 Jun 2:S0272-6386(20)30613-2.
4.       Koraishy FM, Yamout H, Naik AS, Zhang Z, Schnitzler MA, Ouseph R, Lam NN, Dharnidharka VR, Axelrod D, Hess GP, Segev DL, Kasiske BL, Lentine KL. Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation. Clin Transplant. 2020 Mar;34(3):e13803.
5.       Alhamad T, Koraishy FM, Lam NN, Katari S, Naik AS, Schnitzler MA, Xiao H, Axelrod DA, Dharnidharka VR, Randall H, Ouseph R, Segev DL, Brennan DC, Devraj R, Kasiske BL, Lentine KL. Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. Transplantation. 2019 Nov;103(11):2373-2382.
6.       Lentine KL, Koraishy FM, Sarabu N, Naik AS, Lam NN, Garg AX, Axelrod D, Zhang Z, Hess GP, Kasiske BL, Segev DL, Henderson ML, Massie AB, Holscher CM, Schnitzler MA. Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records. Clin Transplant. 2019 Oct;33(10):e13696.
7.       Cheng XS, Lentine KL, Koraishy FM, Myers J, Tan JC. Implications of Frailty for Peritransplant Outcomes in Kidney Transplant Recipients. Curr Transplant Rep. 2019 Mar;6(1):16-25.
8.       Koraishy FM, Salas J, Neylan TC, Cohen BE, Schnurr PP, Clouston S, Scherrer JF. Association of Severity of Posttraumatic Stress Disorder With Inflammation: Using Total White Blood Cell Count as a Marker". Version 2. Chronic Stress (Thousand Oaks). 2019 Jan-Dec;3:2470547019877651.
9.       Al-Taee AM , Almaskeen SA, Koraishy FM. Minimal change disease associated with balsalazide therapy for ulcerative colitis. J Nephropathol. 2019;8(4): e39.


Post-traumatic Stress Disorder as a novel risk factor for Chronic Kidney Disease

Chronic Kidney Disease (CKD) is common and carries a high risk of morbidity and mortality. Novel risk factors are needed to identify patients at early stages of CKD that are at highest risk of progression. Major depression has been linked with CKD. Posttraumatic stress disorder (PTSD), a chronic stress condition, commonly comorbid with depression, is associated with CKD risk factors including inflammation, cardiovascular disease, hypertension and diabetes. To date, no studies have examined whether PTSD is associated with CKD. In this study, we propose to determine the association of PTSD with progressive CKD and whether this association is increased in patients with depression or high levels of inflammation. We will use clinical and biomarker data from two prospective cohorts: ‘Stony Brook World Trade Center Responder Cohort’ and the ‘Heart and Soul Study’. Preliminary data generated from these analyses will be used for a career development award application.

Characterization of AKI with outcomes in patients with COVID-19

The purpose of this project is to characterize acute kidney injury (AKI) COVID-19 patients and to determine the association of chronic kidney disease (CKD)/end-stage renal disease (ESRD), hypertension (HTN), intravenous fluids (IVFs) & angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) with outcomes (AKI, mechanical ventilation and death in COVID-19 patients

Specific Aims:
1. Determine the type of AKI and its associated risk factors in patients with COVID-19 disease.
2. Determine the association of CKD/ESRD with AKI, ARDS and death in patients with COVID-19 disease.
3. Determine the association of HTN with AKI, ARDS and death in patients with COVID-19 disease.
4. Determine the association of ACEI/ARBs with AKI, ARDS and death in patients with COVID-19 disease.
5. Determine the association of IVFs with AKI, ARDS and death in patients with COVID-19 disease.

Follow-up study of patients hospitalized with AKI and COVID-19 at Stony Brook University Hospital

This is an observational prospective study to determine the post-discharge outcomes of patients admitted at Stony Brook Hospital for acute kidney injury (AKI) and COVID-19 between March 2020 and May 2020.